Adverse event totals18

The totals the trial posted for each group.

1 to 18 of 18

Total	Group	Affected	At risk
Total, all-cause mortality	Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	35	63
Total, all-cause mortality	Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	33	59
Total, all-cause mortality	Cohort C (FL): RTX + Polatuzumab	6	20
Total, all-cause mortality	Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab	4	9
Total, all-cause mortality	Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab	8	40
Total, all-cause mortality	Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab	32	40
Total, other adverse events	Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	63	63
Total, other adverse events	Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	58	59
Total, other adverse events	Cohort C (FL): RTX + Polatuzumab	20	20
Total, other adverse events	Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab	9	9
Total, other adverse events	Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab	37	40
Total, other adverse events	Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab	38	40
Total, serious adverse events	Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab	27	63
Total, serious adverse events	Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab	21	59
Total, serious adverse events	Cohort C (FL): RTX + Polatuzumab	8	20
Total, serious adverse events	Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab	3	9
Total, serious adverse events	Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab	9	40
Total, serious adverse events	Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab	18	40

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01691898/event-totals